Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. News
Inhibrx Biosciences, Inc. Quantitative Score
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Inhibrx Biosciences, Inc. Financials
Table Compare
Compare INBX metrics with: | |||
|---|---|---|---|
Earnings & Growth | INBX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | INBX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | INBX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | INBX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Inhibrx Biosciences, Inc. Income
Inhibrx Biosciences, Inc. Balance Sheet
Inhibrx Biosciences, Inc. Cash Flow
Inhibrx Biosciences, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Neutral |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Inhibrx Biosciences, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.8500 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2024-06-20 | 0.85 | Quarterly |
Historical Market Cap
Shares Outstanding
Inhibrx Biosciences, Inc. Executives
| Name | Role |
|---|---|
| Ms. Kelly Devine Deck B.S., CPA, M.S. | Executive Vice President, Chief Financial Officer & Treasurer |
| Mr. Mark Paul Lappe | Founder, Chief Executive Officer & Chairman |
| Ms. Leah Pollema J.D. | Vice President, General Counsel & Corporate Secretary |
| Dr. Ashraf Amanullah Ph.D. | Executive Vice President & Chief Technical Operations Officer |
| Mr. David J. Matly M.B.A. | President and Chief Commercial & Business Development Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Kelly Devine Deck B.S., CPA, M.S. | Executive Vice President, Chief Financial Officer & Treasurer | Female | 1980 | 2.19M |
| Mr. Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | Male | 1967 | 1.13M |
| Ms. Leah Pollema J.D. | Vice President, General Counsel & Corporate Secretary | Female | -- | |
| Dr. Ashraf Amanullah Ph.D. | Executive Vice President & Chief Technical Operations Officer | 1968 | -- | |
| Mr. David J. Matly M.B.A. | President and Chief Commercial & Business Development Officer | Male | 1986 | -- |
Inhibrx Biosciences, Inc. Insider Trades
| Date | 28 May |
| Name | MANHARD KIMBERLY |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | 28 May |
| Name | Vuori Kristiina MD |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | 28 May |
| Name | Kayyem Jon Faiz |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | 28 May |
| Name | FORSYTH DOUGLAS |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | 1 Apr |
| Name | Deck Kelly |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 28 May | MANHARD KIMBERLY | Director | Acquired | A-Award | 15000 |
| 28 May | Vuori Kristiina MD | Director | Acquired | A-Award | 15000 |
| 28 May | Kayyem Jon Faiz | Director | Acquired | A-Award | 15000 |
| 28 May | FORSYTH DOUGLAS | Director | Acquired | A-Award | 15000 |
| 1 Apr | Deck Kelly | Chief Financial Officer | Acquired | A-Award | 15000 |